UCPMP 2024: India's new pharma marketing code mandates ethics panels, bans doctor gifts
Synopsis
India's overhauled pharma marketing code now forces companies to set up formal Ethics Committees, appoint Ethics Officers, and publicly disclose marketing spend — while banning gifts and hospitality to doctors outright. The 2025 amendment added annual expenditure reporting, closing a loophole that critics said allowed covert marketing under the guise of medical education.
Key Takeaways
The UCPMP, 2024 was notified by the Department of Pharmaceuticals on 12 April 2024 , replacing the UCPMP, 2015 .
Pharma companies must now constitute Ethics Committees for Pharmaceutical Marketing Practices (ECPMPs) and appoint dedicated Ethics Officers .
Gifts, monetary benefits, and hospitality to doctors and their family members are explicitly prohibited .
A two-layer complaint redressal mechanism has been established, with appeals handled by the Department of Pharmaceuticals .
Amendments notified in September 2025 require companies to submit annual marketing expenditure statements on the government platform.
Companies are accountable for the actions of their medical representatives and may face independent, random, or risk-based audits.
India's Uniform Code for Pharmaceutical Marketing Practices (UCPMP), 2024, notified by the Centre's Department of Pharmaceuticals on 12 April 2024, introduces sweeping ethical safeguards for pharmaceutical marketing — including mandatory Ethics Committees, appointed Ethics Officers, and a blanket ban on gifts and hospitality to doctors. The framework, which supersedes the UCPMP, 2015, was disclosed to Parliament on Friday, 25 July 2025, in a written reply by Minister of State for Chemicals and Fertilisers Anupriya Patel.
What the New Code Mandates
The UCPMP, 2024 requires every pharmaceutical company to constitute an Ethics Committee for Pharmaceutical Marketing Practices (ECPMP) and designate an Ethics Officer responsible for overseeing compliance. Companies must also submit self-declarations affirming adherence to the code and disclose prescribed marketing expenditure annually on the relevant government platform.
A two-layer complaint adjudication mechanism has been established, with first-level redressal handled internally and appeals escalated to the Department of Pharmaceuticals. Companies may additionally be subjected to independent, random, or risk-based audits to verify compliance.
Regulating Doctor-Industry Interactions
A central pillar of the code is the strict regulation of interactions between pharmaceutical company representatives and healthcare professionals and healthcare organisations. The code explicitly prohibits the provision of gifts, monetary benefits, and hospitality — including to doctors' family members — by pharmaceutical companies or their medical representatives.
Pharmaceutical companies are held directly accountable for the conduct of their medical representatives and other employees engaged in promotional activities. Guidelines governing drug promotion among doctors have been comprehensively outlined within the code.
Transparency on Medical Education Spending
The code requires companies to disclose expenditures related to conferences, seminars, and workshops organised for continuing medical education (CME) and continuing professional development (CPD). This transparency requirement is aimed at preventing covert marketing disguised as educational activity — a practice that has drawn regulatory scrutiny globally.
2025 Amendments: Tightening Disclosure Requirements
The code was further amended in September 2025 to streamline implementation and strengthen disclosure norms. The amendments specifically require companies to submit annual statements of marketing expenditure on the designated platform, adding a layer of accountability that was absent in the original 2024 notification. Minister Patel confirmed these details in her written Lok Sabha reply.
Context and Significance
The UCPMP, 2024 replaces a nine-year-old voluntary framework that critics argued lacked enforcement teeth. India's pharmaceutical sector — the world's third-largest by volume — has faced longstanding concerns over unethical marketing practices, including undisclosed doctor incentives. This is the first version of the code to mandate formal institutional structures such as ECPMPs and Ethics Officers, marking a structural shift from self-regulation to supervised compliance. The move aligns India more closely with regulatory standards in the European Union and the United States, where industry-doctor financial relationships are subject to mandatory public disclosure.
Point of View
2024 is a meaningful structural upgrade over its predecessor, but its impact will hinge entirely on enforcement — an area where India's pharmaceutical self-regulation has historically underperformed. Mandating Ethics Committees and Officers is sound architecture, yet these bodies sit within the very companies they are meant to police. The two-layer appellate mechanism, with the Department of Pharmaceuticals as the final arbiter, raises questions about bandwidth and independence. India's pharma sector is the world's third-largest by volume, and the scale of doctor-industry interaction dwarfs what voluntary codes have ever been able to govern. The 2025 amendment's annual expenditure disclosure requirement is the most consequential addition — but only if the data is made publicly accessible and cross-referenced against CME activity, which the current framework does not explicitly require.
NationPress
24 Jul 2026
Frequently Asked Questions
What is the UCPMP 2024?
The Uniform Code for Pharmaceutical Marketing Practices (UCPMP), 2024 is a regulatory framework notified by India's Department of Pharmaceuticals on 12 April 2024, replacing the earlier UCPMP, 2015. It governs how pharmaceutical companies market their products, interact with doctors, and disclose marketing expenditure.
What does the UCPMP 2024 ban?
The code explicitly prohibits pharmaceutical companies from providing gifts, monetary benefits, or hospitality to doctors and their family members. Medical representatives and other employees are covered under this ban, and companies are held accountable for their conduct.
What are Ethics Committees for Pharmaceutical Marketing Practices?
Ethics Committees for Pharmaceutical Marketing Practices (ECPMPs) are mandatory internal bodies that pharmaceutical companies must now constitute under the UCPMP, 2024. They oversee compliance with the code's ethical marketing standards, supported by a designated Ethics Officer within each company.
How does the complaint mechanism work under the new code?
The UCPMP, 2024 establishes a two-layer complaint adjudication process. Complaints are first addressed at the company level, with appeals escalated to the Department of Pharmaceuticals, which serves as the final appellate authority.
What changed with the September 2025 amendment to the UCPMP?
The September 2025 amendment tightened disclosure and implementation requirements by mandating that pharmaceutical companies submit annual statements of marketing expenditure on the designated government platform. This was aimed at closing gaps in transparency around spending on conferences, seminars, and medical education events.
